---
schema_version: "secwatch.filing_event.v1"
accession: "0001326190-23-000003"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T21:24:33.377530+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Altimmune Q4 2022 net loss $21.7M; cash $184.9M; pemvidutide obesity interim readout expected March 2023

## Summary
- Net loss for Q4 2022 was $21.7M ($0.43 per share) vs $23.9M ($0.57) in Q4 2021; revenue negligible.
- Cash, cash equivalents and short-term investments totaled $184.9M at December 31, 2022.
- R&D expenses $19.2M in Q4 2022, including $13.4M for pemvidutide and $1.9M for HepTcell.
- MOMENTUM Phase 2 obesity trial 24-week interim readout expected in March 2023; Phase 2b NASH trial initiation expected mid-2023.
- HepTcell Phase 2 enrollment >90% complete; data readout expected first half 2024.

## SEC filing metadata
- accession: 0001326190-23-000003
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000132619023000003/0001326190-23-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000132619023000003/alt-20230228x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326190-23-000003
- JSON: https://secwatch.observer/filing/0001326190-23-000003.json
- Plain text: https://secwatch.observer/filing/0001326190-23-000003.txt

## Key facts
- Earnings Releases
  Altimmune, Inc. reported the three months ended December 31, 2022 results: net income $21.7 million, EPS $0.43 net loss per share.
  - Period: the three months ended December 31, 2022
  - Net income: $21.7 million
  - EPS: $0.43 net loss per share
  - Result: reported results
  source text: Net loss for the three months ended December 31, 2022 was $21.7 million, or $0.43 net loss per share, compared to a net loss of $23.9 million, or $0.57 net loss per share, in the same period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326190/000132619023000003/0001326190-23-000003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.